ST-segment elevation myocardial infarction

[1]  P. Libby,et al.  Reassessing the Mechanisms of Acute Coronary Syndromes: The “Vulnerable Plaque” and Superficial Erosion , 2019, Circulation research.

[2]  Antonio Colombo,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. , 2003, Circulation.

[3]  E. Omerovic,et al.  Outcomes 1 year after thrombus aspiration for myocardial infarction. , 2014, The New England journal of medicine.

[4]  W. Kübler,et al.  Regulation of glycolysis in the ischemic and the anoxic myocardium. , 1970, Journal of molecular and cellular cardiology.

[5]  A. D. de Luna,et al.  Coronary Artery Spasm: A 2009 Update , 2009, Circulation.

[6]  B. Gersh,et al.  Clinical Features, Management, and Prognosis of Spontaneous Coronary Artery Dissection , 2012, Circulation.

[7]  Simon Briscoe,et al.  Exercise-based rehabilitation for heart failure. , 2014, The Cochrane database of systematic reviews.

[8]  G. Hutchins,et al.  Coronary artery embolism and myocardial infarction. , 1978, Annals of internal medicine.

[9]  P. Serruys,et al.  Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents: A Prospective Cohort Study , 2012, Circulation.

[10]  R. Paffenbarger,et al.  Physical activity as an index of heart attack risk in college alumni. , 1978, American journal of epidemiology.

[11]  A. Angelini,et al.  2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. , 2012, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[12]  Marco Roffi,et al.  Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. , 2015, European heart journal.

[13]  G. Niccoli,et al.  Coronary microvascular obstruction in acute myocardial infarction. , 2016, European heart journal.

[14]  J. Ottervanger,et al.  Prognostic Value of Admission Glycosylated Hemoglobin and Glucose in Nondiabetic Patients With ST-Segment–Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention , 2011, Circulation.

[15]  G. Schuler,et al.  Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. , 2012, JACC. Cardiovascular imaging.

[16]  E. Bramucci,et al.  Sirolimus-eluting versus uncoated stents in acute myocardial infarction. , 2006, The New England journal of medicine.

[17]  H. Brenner,et al.  Cardiac troponin T measured by a high-sensitivity assay predicts recurrent cardiovascular events in stable coronary heart disease patients with 8-year follow-up. , 2012, Clinical chemistry.

[18]  N. Sharpe,et al.  Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. , 2000, Circulation.

[19]  Mark E Josephson,et al.  Use of the electrocardiogram in acute myocardial infarction. , 2003, The New England journal of medicine.

[20]  D. Bernhard,et al.  Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[21]  G. Stone,et al.  Quality of life after balloon angioplasty or stenting for acute myocardial infarction. One-year results from the Stent-PAMI trial. , 2001, Journal of the American College of Cardiology.

[22]  J. Tsikouris,et al.  A Review of Available Fibrin‐Specific Thrombolytic Agents Used in Acute Myocardial Infarction , 2001, Pharmacotherapy.

[23]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association , 2018, Circulation.

[24]  H. White,et al.  Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. , 2006, JAMA.

[25]  T. Henry,et al.  Nationwide Analysis of Patients With ST-Segment–Elevation Myocardial Infarction Transferred for Primary Percutaneous Intervention: Findings From the American Heart Association Mission: Lifeline Program , 2015, Circulation. Cardiovascular interventions.

[26]  S. Goto,et al.  Platelet thrombin receptor antagonism and atherothrombosis , 2009, European heart journal.

[27]  E. Donal,et al.  Incidence, timing, predictors and impact of acute heart failure complicating ST-segment elevation myocardial infarction in patients treated by primary percutaneous coronary intervention. , 2016, International journal of cardiology.

[28]  M. Jeong,et al.  Differential Clinical Implications of High-Degree Atrioventricular Block Complicating ST-Segment Elevation Myocardial Infarction according to the Location of Infarction in the Era of Primary Percutaneous Coronary Intervention , 2016, Korean circulation journal.

[29]  D. Kolte,et al.  Trends in Incidence, Management, and Outcomes of Cardiogenic Shock Complicating ST‐Elevation Myocardial Infarction in the United States , 2014, Journal of the American Heart Association.

[30]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[31]  Salim Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.

[32]  D. Andreini,et al.  Long-Term Incremental Prognostic Value of Cardiovascular Magnetic Resonance After ST-Segment Elevation Myocardial Infarction: A Study of the Collaborative Registry on CMR in STEMI. , 2017, JACC. Cardiovascular imaging.

[33]  Jennifer G. Robinson,et al.  Reply: 2013 ACC/AHA guideline on the assessment of cardiovascular risk. , 2014, Journal of the American College of Cardiology.

[34]  Andrea Mazzanti,et al.  2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2016, Revista espanola de cardiologia.

[35]  A. Coats.  CAPRICORN: a story of alpha allocation and beta-blockers in left ventricular dysfunction post-MI. , 2001, International journal of cardiology.

[36]  C. Terkelsen,et al.  Urban and rural implementation of pre-hospital diagnosis and direct referral for primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction. , 2011, European heart journal.

[37]  R. Califf,et al.  Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction* , 2009, Critical care medicine.

[38]  Hiroto Tsujioka,et al.  Multiple coronary lesion instability in patients with acute myocardial infarction as determined by optical coherence tomography. , 2010, The American journal of cardiology.

[39]  G S Wagner,et al.  Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. , 1996, The New England journal of medicine.

[40]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[41]  David Erlinge,et al.  Thrombus aspiration during ST-segment elevation myocardial infarction. , 2013, The New England journal of medicine.

[42]  M. Gelb,et al.  Platelet microparticles are internalized in neutrophils via the concerted activity of 12-lipoxygenase and secreted phospholipase A2-IIA , 2015, Proceedings of the National Academy of Sciences.

[43]  A. Kappetein,et al.  Recognition, assessment and management of the mechanical complications of acute myocardial infarction , 2017, Heart.

[44]  Tiina Heliö,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.

[45]  H. Thiele,et al.  The challenges and impact of microvascular injury in ST-elevation myocardial infarction , 2016, Expert review of cardiovascular therapy.

[46]  L. Newby,et al.  Failure to Launch , 2017, JACC. Basic to translational science.

[47]  A. Astrup,et al.  Consumption of industrial and ruminant trans fatty acids and risk of coronary heart disease: a systematic review and meta-analysis of cohort studies , 2011, European Journal of Clinical Nutrition.

[48]  Lawrence A Leiter,et al.  Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol , 2017, The New England journal of medicine.

[49]  A. Henderson,et al.  Rehabilitation after myocardial infarction trial (RAMIT): multi-centre randomised controlled trial of comprehensive cardiac rehabilitation in patients following acute myocardial infarction , 2011, Heart.

[50]  J. Trickett,et al.  A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. , 2008, The New England journal of medicine.

[51]  H. Diener,et al.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[52]  A. Feher,et al.  Prevention and treatment of no-reflow phenomenon by targeting the coronary microcirculation. , 2014, Reviews in cardiovascular medicine.

[53]  F. Crea,et al.  Contemporary Reviews in Cardiovascular Medicine Mechanisms of Coronary Artery Spasm , 2011 .

[54]  R. Asinger,et al.  ST-segment elevation in conditions other than acute myocardial infarction. , 2003, The New England journal of medicine.

[55]  A. Hoes,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.

[56]  S. Grundy,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[57]  Mike Fisher,et al.  Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial , 2014, The Lancet.

[58]  D. Mozaffarian,et al.  Effects on Coronary Heart Disease of Increasing Polyunsaturated Fat in Place of Saturated Fat: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2010, PLoS medicine.

[59]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[60]  S. Ebrahim,et al.  Exercise based rehabilitation for heart failure. , 2004, The Cochrane database of systematic reviews.

[61]  E. Boersma,et al.  Cardiac rehabilitation in patients with acute coronary syndrome with primary percutaneous coronary intervention is associated with improved 10-year survival. , 2018, European heart journal. Quality of care & clinical outcomes.

[62]  Rachel V. Stankowski,et al.  Management of No-Reflow Phenomenon in the Catheterization Laboratory. , 2017, JACC. Cardiovascular interventions.

[63]  H. Bøtker,et al.  Remote Ischemic Conditioning for Patients With STEMI , 2017, Journal of cardiovascular pharmacology and therapeutics.

[64]  K. Lee,et al.  Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. , 1998, Circulation.

[65]  I. Komuro,et al.  Clinical Impact of Ventricular Tachycardia and/or Fibrillation During the Acute Phase of Acute Myocardial Infarction on In-Hospital and 5-Year Mortality Rates in the Percutaneous Coronary Intervention Era. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[66]  Steven Mann,et al.  Differential Effects of Aerobic Exercise, Resistance Training and Combined Exercise Modalities on Cholesterol and the Lipid Profile: Review, Synthesis and Recommendations , 2013, Sports Medicine.

[67]  H. Crijns,et al.  Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: Results of a meta-analysis of 845 patients , 2001 .

[68]  E. Antman,et al.  Coronary Artery Spasm , 1986 .

[69]  Mintu P Turakhia,et al.  Moving From Big Data to Deep Learning-The Case of Atrial Fibrillation. , 2018, JAMA cardiology.

[70]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[71]  M S Golden,et al.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.

[72]  R. Dreyer,et al.  Systematic Review of Patients Presenting With Suspected Myocardial Infarction and Nonobstructive Coronary Arteries , 2015, Circulation.

[73]  Jeroen J. Bax,et al.  Fourth universal definition of myocardial infarction (2018). , 2018, European heart journal.

[74]  B. Carter.  2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology , 2013 .

[75]  D. Benz,et al.  The right timing for post-ischemic stunning , 2017, Journal of Nuclear Cardiology.

[76]  E. Vicaut,et al.  Prehospital ticagrelor in ST-segment elevation myocardial infarction. , 2014, The New England journal of medicine.

[77]  Daniel E Forman,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[78]  Akiko Maehara,et al.  A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.

[79]  W. Gibler,et al.  Guideline implementation research: exploring the gap between evidence and practice in the CRUSADE Quality Improvement Initiative. , 2007, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[80]  R. Virmani,et al.  Concept of vulnerable/unstable plaque. , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[81]  R. Mehran,et al.  Acute myocardial infarction in young women: current perspectives , 2018, International journal of women's health.

[82]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[83]  J Wouter Jukema,et al.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018, The New England journal of medicine.

[84]  Manesh R. Patel,et al.  Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. , 2014, JAMA.

[85]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[86]  C. Stefanadis,et al.  Coronary Atherosclerotic Vulnerable Plaque: Current Perspectives , 2017, Journal of the American Heart Association.

[87]  C. Macaya,et al.  STEMI Interventions: The European Perspective and Stent for Life Initiative. , 2012, Interventional cardiology clinics.

[88]  P. Armstrong,et al.  Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. , 2009, JAMA.

[89]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[90]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[91]  Alan D. Lopez,et al.  Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015 , 2017, Journal of the American College of Cardiology.

[92]  Gary S. Mintz,et al.  The dynamic nature of coronary artery lesion morphology assessed by serial virtual histology intravascular ultrasound tissue characterization. , 2010, Journal of the American College of Cardiology.

[93]  Brian Savage,et al.  Initiation of Platelet Adhesion by Arrest onto Fibrinogen or Translocation on von Willebrand Factor , 1996, Cell.

[94]  D. Burns.  Epidemiology of smoking-induced cardiovascular disease. , 2003, Progress in cardiovascular diseases.

[95]  Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. , 1981, The New England journal of medicine.

[96]  D. Levy,et al.  Temporal Trends in Coronary Heart Disease Mortality and Sudden Cardiac Death From 1950 to 1999: The Framingham Heart Study , 2004, Circulation.

[97]  A. Jaffe,et al.  A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .

[98]  P. Libby,et al.  Low‐Dose Methotrexate for the Prevention of Atherosclerotic Events , 2019, The New England journal of medicine.

[99]  E. Falk,et al.  Plaque Erosion: New Insights From the Road Less Travelled. , 2017, Circulation research.

[100]  L. Tokgozoglu,et al.  Trends in Gender Differences in Cardiac Care and Outcome After Acute Myocardial Infarction in Western Sweden: A Report From the Swedish Web System for Enhancement of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) , 2015, Journal of the American Heart Association.

[101]  R. Califf,et al.  Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. , 2005, American heart journal.

[102]  M. Nahrendorf,et al.  Leukocyte Behavior in Atherosclerosis, Myocardial Infarction, and Heart Failure , 2013, Science.

[103]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[104]  M. Nakamura,et al.  Clinical characteristics and long-term prognosis of patients with variant angina. A comparative study between western and Japanese populations. , 1988, International journal of cardiology.

[105]  H. Arnesen,et al.  Warfarin, aspirin, or both after myocardial infarction. , 2002, The New England journal of medicine.

[106]  P. Thompson,et al.  Exercise at the Extremes: The Amount of Exercise to Reduce Cardiovascular Events. , 2016, Journal of the American College of Cardiology.

[107]  J. Hare,et al.  What Is the Future of Cell-Based Therapy for Acute Myocardial Infarction , 2017, Circulation research.

[108]  S. Goto,et al.  Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling. , 2006, Journal of the American College of Cardiology.

[109]  H. Krumholz,et al.  Angina at 1 year after myocardial infarction: prevalence and associated findings. , 2008, Archives of internal medicine.

[110]  K. Filion,et al.  The effectiveness and safety of the Impella ventricular assist device for high‐risk percutaneous coronary interventions: A systematic review , 2018, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[111]  D Kromhout,et al.  Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. , 1995, JAMA.

[112]  E. Antman,et al.  Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. , 2008, Journal of the American College of Cardiology.

[113]  C. Frampton,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. , 1998, Circulation.

[114]  P. Vokonas,et al.  Effect of propranolol in reducing mortality in older myocardial infarction patients. The Beta-Blocker Heart Attack Trial experience. , 1983, Circulation.

[115]  D. Atar,et al.  ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. , 2016, European heart journal.

[116]  Yaiza Beatriz Molero-Díez,et al.  Fourth universal definition of myocardial infarction , 2019, Colombian Journal of Anesthesiology.

[117]  T. Nagai,et al.  Prevalence, Clinical Features, and Prognosis of Acute Myocardial Infarction Attributable to Coronary Artery Embolism , 2015, Circulation.

[118]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[119]  Christopher P Cannon,et al.  A Call to ACTION (Acute Coronary Treatment and Intervention Outcomes Network): A National Effort to Promote Timely Clinical Feedback and Support Continuous Quality Improvement for Acute Myocardial Infarction , 2009, Circulation. Cardiovascular quality and outcomes.

[120]  T. Jernberg,et al.  Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. , 2015, European heart journal.

[121]  Waller Bf.  Atherosclerotic and nonatherosclerotic coronary artery factors in acute myocardial infarction. , 1989 .

[122]  P. Damman,et al.  MULTIPLE BIOMARKERS AT ADMISSION SIGNIFICANTLY IMPROVE THE PREDICTION OF MORTALITY IN PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION , 2013 .

[123]  Y. Cha,et al.  Long-Term Outcomes in Survivors of Early Ventricular Arrhythmias After Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention. , 2016, The American journal of cardiology.

[124]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[125]  M. Kobusiak-Prokopowicz.  [Obesity and cardiovascular diseases]. , 1999, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

[126]  T. Rea,et al.  Impact of Regionalization of ST-Segment–Elevation Myocardial Infarction Care on Treatment Times and Outcomes for Emergency Medical Services–Transported Patients Presenting to Hospitals With Percutaneous Coronary Intervention: Mission Lifeline Accelerator-2 , 2017, Circulation.

[127]  Baris Gencer,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2011 .

[128]  J. Saw.  Spontaneous coronary artery dissection. , 2013, The Canadian journal of cardiology.

[129]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[130]  C. Hamm,et al.  Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine , 2005, Heart.

[131]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[132]  B. Gersh,et al.  Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial , 2011, The Lancet.

[133]  G. Maurer,et al.  Gender differences in short- and long-term mortality in the Vienna STEMI registry. , 2017, International journal of cardiology.

[134]  V. Fuster,et al.  Coronary artery disease: pathogenesis and acute coronary syndromes. , 2001, The Mount Sinai journal of medicine, New York.

[135]  A. Giannopoulos,et al.  Vulnerable plaque imaging: updates on new pathobiological mechanisms. , 2015, European heart journal.

[136]  E. Vicaut,et al.  Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial , 2011, The Lancet.

[137]  Rong Li,et al.  Clinical efficacy and safety of autologous stem cell transplantation for patients with ST-segment elevation myocardial infarction , 2016, Therapeutics and clinical risk management.

[138]  Garth N Graham.  Racial and Ethnic Differences in Acute Coronary Syndrome and Myocardial Infarction Within the United States: From Demographics to Outcomes , 2016, Clinical cardiology.

[139]  R. West,et al.  β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction , 2017, Journal of the American College of Cardiology.

[140]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (1). , 1992, The New England journal of medicine.

[141]  W. Weaver,et al.  Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. , 2008, American heart journal.

[142]  S. Priori,et al.  2015 European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death summarized by co-chairs. , 2015, European heart journal.

[143]  M. Nahrendorf,et al.  Innate immune cells in ischaemic heart disease: does myocardial infarction beget myocardial infarction? , 2016, European heart journal.

[144]  Laura Mauri,et al.  2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Journal of the American College of Cardiology.

[145]  M. Banach,et al.  Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. , 2017, Journal of the American College of Cardiology.

[146]  Jian-Min Yuan,et al.  The Alternative Healthy Eating Index Is Associated with a Lower Risk of Fatal and Nonfatal Acute Myocardial Infarction in a Chinese Adult Population. , 2016, The Journal of nutrition.

[147]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[148]  R. Califf,et al.  Prognostic significance of isolated sinus tachycardia during first three days of acute myocardial infarction. , 1984, The American journal of medicine.

[149]  L. Newby,et al.  Characterization and outcomes of women and men with non-ST-segment elevation myocardial infarction and nonobstructive coronary artery disease: results from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRU , 2009, American heart journal.

[150]  P. Scarborough,et al.  Differences in coronary heart disease, stroke and cancer mortality rates between England, Wales, Scotland and Northern Ireland: the role of diet and nutrition , 2011, BMJ Open.

[151]  Jeroen J. Bax,et al.  Machine Learning for Electrocardiographic Diagnosis of Left Ventricular Early Diastolic Dysfunction. , 2018, Journal of the American College of Cardiology.

[152]  M. Prinzmetal,et al.  Angina pectoris. I. A variant form of angina pectoris; preliminary report. , 1959, The American journal of medicine.

[153]  Thach N. Nguyen,et al.  Percutaneous coronary intervention in patients with active bleeding or high bleeding risk. , 2012, Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology.

[154]  B. McNally,et al.  Integration of pre-hospital electrocardiograms and ST-elevation myocardial infarction receiving center (SRC) networks: impact on Door-to-Balloon times across 10 independent regions. , 2009, JACC. Cardiovascular interventions.

[155]  Judy Buttriss.  The Eatwell Guide refreshed , 2016 .

[156]  E. Antman,et al.  Use of Emergency Medical Service Transport Among Patients With ST-Segment–Elevation Myocardial Infarction: Findings From the National Cardiovascular Data Registry Acute Coronary Treatment Intervention Outcomes Network Registry–Get With the Guidelines , 2011, Circulation.

[157]  G. Vanzetto,et al.  Prevalence, therapeutic management and medium-term prognosis of spontaneous coronary artery dissection: results from a database of 11,605 patients. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[158]  S. Blair,et al.  Physical fitness and activity as separate heart disease risk factors: a meta-analysis. , 2001, Medicine and science in sports and exercise.

[159]  J. Gore,et al.  Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events [GRACE]). , 2004, The American journal of cardiology.

[160]  Sunil V. Rao,et al.  Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial , 2015, The Lancet.

[161]  S. Pocock,et al.  Global geographical variations in ST-segment elevation myocardial infarction management and post-discharge mortality. , 2017, International journal of cardiology.

[162]  T. Henry,et al.  Benefit of Transferring ST-Segment–Elevation Myocardial Infarction Patients for Percutaneous Coronary Intervention Compared With Administration of Onsite Fibrinolytic Declines as Delays Increase , 2011, Circulation.

[163]  C. Cannon,et al.  Acute myocardial infarction , 2017, The Lancet.

[164]  R Dietz,et al.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.

[165]  P. Libby.  Mechanisms of acute coronary syndromes and their implications for therapy. , 2013, The New England journal of medicine.

[166]  A. Hoes,et al.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. , 2016, European heart journal.

[167]  C. Berry,et al.  Randomized trial of preventive angioplasty in myocardial infarction. , 2013, The New England journal of medicine.

[168]  P. Damman,et al.  P2Y12 platelet inhibition in clinical practice , 2011, Journal of Thrombosis and Thrombolysis.

[169]  A. Remppis,et al.  Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. , 1991, The American journal of cardiology.

[170]  M. Montaudon,et al.  Myocarditis or "true" infarction by cardiac magnetic resonance in patients with a clinical diagnosis of myocardial infarction without obstructive coronary disease: A meta-analysis of individual patient data. , 2015, Atherosclerosis.

[171]  R. Collins,et al.  Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.

[172]  John S Rumsfeld,et al.  Door-to-balloon time and mortality among patients undergoing primary PCI. , 2013, The New England journal of medicine.

[173]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[174]  M. Taskinen,et al.  [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.

[175]  M. Sabatine,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. , 2001, The New England journal of medicine.

[176]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[177]  Paul Burton,et al.  Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[178]  Jeroen J. Bax,et al.  International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology , 2018, European heart journal.

[179]  J. Ferrières,et al.  Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. , 2012, JAMA.

[180]  G. Filippatos,et al.  Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. , 2005, European heart journal.

[181]  V. Govindarajan.  Ginger--chemistry, technology, and quality evaluation: part 1. , 1982, Critical reviews in food science and nutrition.

[182]  H. Swanton,et al.  Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[183]  S. Solomon,et al.  The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). , 2006, Journal of the American College of Cardiology.

[184]  P. Steg,et al.  Clinical evidence for oral antiplatelet therapy in acute coronary syndromes , 2015, The Lancet.

[185]  I. Benedek,et al.  Impact of a Preexisting STEMI Network in Improving STEMI Diagnostic and Treatment in the Community after the Introduction of a National Program of Interventional Treatment in Acute myocardial Infarction , 2015 .

[186]  E. Braunwald,et al.  TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. , 1997, Circulation.

[187]  H. Thiele,et al.  Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials , 2017, European heart journal.

[188]  G. Biondi-Zoccai,et al.  Recurrent angina after coronary revascularization: a clinical challenge. , 2007, European heart journal.

[189]  S. Girotra,et al.  Radial versus femoral access for primary percutaneous interventions in ST-segment elevation myocardial infarction patients: a meta-analysis of randomized controlled trials. , 2013, JACC. Cardiovascular interventions.

[190]  A. Go,et al.  Should the electrocardiogram be used to guide therapy for patients with left bundle-branch block and suspected myocardial infarction? , 1999, JAMA.

[191]  J. Robson,et al.  Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease , 2007, Heart.

[192]  A. Jaffe,et al.  Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. , 2000, American heart journal.

[193]  Lisa Hartling,et al.  Meta-Analysis: Secondary Prevention Programs for Patients with Coronary Artery Disease , 2005, Annals of Internal Medicine.

[194]  R. Paffenbarger,et al.  Physical activity as an index of heart attack risk in college alumni. 1978. , 1995, American journal of epidemiology.

[195]  Sunil V. Rao,et al.  Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial , 2011, The Lancet.

[196]  P. Serruys,et al.  Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial , 2012, The Lancet.

[197]  Patrice Cacoub,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.

[198]  J. Fraser,et al.  Veno-Arterial ECMO in the Setting of Post-Infarct Ventricular Septal Defect: A Bridge to Surgical Repair. , 2016, Heart, lung & circulation.

[199]  Jiang He,et al.  Effect of Aerobic Exercise on Blood Pressure , 2002, Annals of Internal Medicine.

[200]  E. Ohman,et al.  Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials , 2017, European heart journal.

[201]  B. Brodie,et al.  Door-to-balloon time with primary percutaneous coronary intervention for acute myocardial infarction impacts late cardiac mortality in high-risk patients and patients presenting early after the onset of symptoms. , 2006, Journal of the American College of Cardiology.

[202]  S. Hernandez-Resendiz,et al.  Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities , 2018, Pharmacology & therapeutics.

[203]  T. Fukui,et al.  Differential Time Trends of Outcomes and Costs of Care for Acute Myocardial Infarction Hospitalizations by ST Elevation and Type of Intervention in the United States, 2001–2011 , 2015, Journal of the American Heart Association.

[204]  Sunil V. Rao,et al.  Randomized trial of primary PCI with or without routine manual thrombectomy. , 2015, The New England journal of medicine.

[205]  G. Boysen,et al.  European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.

[206]  E. Aliot,et al.  A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. , 1995, The New England journal of medicine.

[207]  Sohail Q Khan,et al.  Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. , 2009, European heart journal.

[208]  L. Wallentin,et al.  Persistent Cardiac Troponin I Elevation in Stabilized Patients After an Episode of Acute Coronary Syndrome Predicts Long-Term Mortality , 2007, Circulation.

[209]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[210]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[211]  G. Lamas,et al.  Coronary intervention for persistent occlusion after myocardial infarction. , 2006, The New England journal of medicine.

[212]  A. Morrison,et al.  Sodium intake and cardiovascular disease. , 2011, Annual review of public health.

[213]  T. Akasaka,et al.  Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. , 2014, Journal of the American College of Cardiology.

[214]  M. Pfeffer,et al.  VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context , 2003, European journal of heart failure.

[215]  E. Boerwinkle,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. , 2003, Circulation.

[216]  J. Spertus,et al.  Derivation and Validation of a Risk Standardization Model for Benchmarking Hospital Performance for Health-Related Quality of Life Outcomes After Acute Myocardial Infarction , 2014, Circulation.

[217]  R. Califf,et al.  Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. , 1999, The American journal of cardiology.

[218]  B. Yawn,et al.  Incidence of heart failure after myocardial infarction: is it changing over time? , 2003, American journal of epidemiology.

[219]  C. Lang,et al.  The prognostic value of high sensitivity troponin T 7 weeks after an acute coronary syndrome , 2012, Heart.

[220]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[221]  E. Ohman,et al.  Management of cardiogenic shock. , 2015, European heart journal.

[222]  J. Saw,et al.  Spontaneous coronary artery dissection-A review. , 2015, Cardiovascular diagnosis and therapy.

[223]  Yong Wang,et al.  Physical exercise-induced protection on ischemic cardiovascular and cerebrovascular diseases. , 2015, International journal of clinical and experimental medicine.

[224]  R. Swaminathan,et al.  Temporal Trends in the Clinical Acuity of Patients with ST-Segment Elevation Myocardial Infarction. , 2018, The American journal of medicine.

[225]  Nick Freemantle,et al.  β Blockade after myocardial infarction: systematic review and meta regression analysis , 1999 .

[226]  N. Rehnqvist,et al.  Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. , 1985, Journal of the American College of Cardiology.

[227]  G. Stone,et al.  Comparison of one-year outcomes after percutaneous coronary intervention among current smokers, ex-smokers, and nonsmokers. , 2002, American Journal of Cardiology.

[228]  J. Hill,et al.  Theophylline for the Treatment of Atrioventricular Block after Myocardial Infarction , 1995, Annals of Internal Medicine.

[229]  Michael S Marber,et al.  Cardiac troponins: from myocardial infarction to chronic disease , 2017, Cardiovascular research.

[230]  M. van der Schaar,et al.  Sex Differences in Outcomes After STEMI: Effect Modification by Treatment Strategy and Age , 2018, JAMA Internal Medicine.

[231]  Renu Virmani,et al.  Intraplaque hemorrhage and progression of coronary atheroma. , 2003, The New England journal of medicine.

[232]  J. Messenger,et al.  Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. , 2010, Journal of the American College of Cardiology.

[233]  J. Spertus,et al.  Association of Smoking Status With Angina and Health-Related Quality of Life After Acute Myocardial Infarction , 2015, Circulation. Cardiovascular quality and outcomes.

[234]  K. Yin,et al.  Sex differences in vascular physiology and pathophysiology: estrogen and androgen signaling in health and disease. , 2017, American journal of physiology. Heart and circulatory physiology.

[235]  L. Newby,et al.  Frequency and consequences of recording an electrocardiogram >10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE Initiative). , 2006, The American journal of cardiology.

[236]  M. Budoff,et al.  Coronary Calcium Score and Cardiovascular Risk. , 2018, Journal of the American College of Cardiology.

[237]  P. Armstrong,et al.  Electrocardiographic identification of the culprit coronary artery in inferior wall ST elevation myocardial infarction. , 2010, The Canadian journal of cardiology.

[238]  S. Takagi,et al.  Platelets: Small in Size But Essential in the Regulation of Vascular Homeostasis - Translation From Basic Science to Clinical Medicine. , 2015, Circulation journal : official journal of the Japanese Circulation Society.

[239]  N. Benowitz.  Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. , 2003, Progress in cardiovascular diseases.

[240]  J. Ornato,et al.  Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. , 2008, American heart journal.

[241]  J. Alpert,et al.  How to use high-sensitivity cardiac troponins in acute cardiac care. , 2013, European heart journal.

[242]  G. Maurer,et al.  Implementation of Guidelines Improves the Standard of Care: The Viennese Registry on Reperfusion Strategies in ST-Elevation Myocardial Infarction (Vienna STEMI Registry) , 2006, Circulation.

[243]  G. Schuler,et al.  Intraaortic balloon support for myocardial infarction with cardiogenic shock. , 2012, The New England journal of medicine.

[244]  C. O'connor,et al.  Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI). , 2010, The American journal of cardiology.

[245]  K. Peter,et al.  Current and future antiplatelet therapies: emphasis on preserving haemostasis , 2018, Nature Reviews Cardiology.

[246]  G. Mensah,et al.  1990-2010 global cardiovascular disease atlas. , 2014, Global heart.

[247]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[248]  J. Spertus,et al.  ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, Am , 2012, Journal of the American College of Cardiology.

[249]  J. Spertus,et al.  Association Between Cardiac Rehabilitation Participation and Health Status Outcomes After Acute Myocardial Infarction. , 2016, JAMA cardiology.

[250]  N. Frangogiannis.  Pathophysiology of Myocardial Infarction. , 2015, Comprehensive Physiology.

[251]  J. Rouleau,et al.  Mechanism of Relief of Pacing-induced Angina with Oral Verapamil: Reduced Oxygen Demand , 1983, Circulation.

[252]  Y. Kishon,et al.  Early and late atrioventricular block in acute inferior myocardial infarction. , 1984, Journal of the American College of Cardiology.

[253]  M. Trenell,et al.  Physical Activity in the Management of Patients with Coronary Artery Disease: A Review , 2015, Cardiology in review.

[254]  ISIS-1 Collaborative Group.  RANDOMISED TRIAL OF INTRAVENOUS ATENOLOL AMONG 16 027 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-1 , 1986, The Lancet.

[255]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[256]  R. Jennings.  Historical perspective on the pathology of myocardial ischemia/reperfusion injury. , 2013, Circulation research.

[257]  H. Thiele,et al.  PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock , 2017, The New England journal of medicine.

[258]  V. Fuster,et al.  Global Perspective on Acute Coronary Syndrome: A Burden on the Young and Poor , 2014, Circulation research.

[259]  D. Hausenloy,et al.  Myocardial Infarct Size by CMR in Clinical Cardioprotection Studies , 2017, JACC. Cardiovascular imaging.

[260]  Yan Zhang,et al.  Stent for Life Initiative: leading example in building STEMI systems of care in emerging countries. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[261]  A. Arai,et al.  Cardiovascular Magnetic Resonance in Acute ST-Segment–Elevation Myocardial Infarction: Recent Advances, Controversies, and Future Directions , 2018, Circulation.

[262]  A. Collins,et al.  Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. , 1998, The New England journal of medicine.

[263]  A. Rabinstein.  Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90 056 participants in 14 randomised trials of statins , 2007 .

[264]  G. Biondi-Zoccai,et al.  Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). , 2010, The American journal of cardiology.

[265]  M. Yamin,et al.  Organisation of reperfusion therapy for STEMI in a developing country , 2015, Open Heart.

[266]  L. Piegas,et al.  Initial clinical results using intracardiac electrogram monitoring to detect and alert patients during coronary plaque rupture and ischemia. , 2010, Journal of the American College of Cardiology.

[267]  Deepak L. Bhatt,et al.  Left Ventricular Thrombus After Acute Myocardial Infarction: Screening, Prevention, and Treatment , 2018, JAMA cardiology.

[268]  L. Correia,et al.  Prognostic Value of TIMI Score versus GRACE Score in ST-segment Elevation Myocardial Infarction , 2014, Arquivos brasileiros de cardiologia.

[269]  A. Federici,et al.  Activation-independent platelet adhesion and aggregation under elevated shear stress. , 2005, Blood.

[270]  D. Berman,et al.  Clinical indications for coronary artery calcium scoring in asymptomatic patients: Expert consensus statement from the Society of Cardiovascular Computed Tomography. , 2017, Journal of cardiovascular computed tomography.

[271]  AccelerateED Task Force.  2018 AHA/ACC guideline for the management of adults with congenital heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines , 2019 .

[272]  C. Lavie,et al.  Obesity and CardiovascularDiseases. , 2017, Current problems in cardiology.

[273]  C. Reid,et al.  Long-term clinical outcomes of transient and persistent no-reflow following percutaneous coronary intervention (PCI): a multicentre Australian registry. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[274]  S. Mehta,et al.  Reperfusion strategies in acute myocardial infarction and multivessel disease , 2017, Nature Reviews Cardiology.

[275]  D. McManus,et al.  Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. , 2011, The American journal of medicine.

[276]  C. Yuan,et al.  Sustained acceleration in carotid atherosclerotic plaque progression with intraplaque hemorrhage: a long-term time course study. , 2012, JACC. Cardiovascular imaging.

[277]  H. Katus,et al.  Prognostic significance of admission cardiac troponin T in patients treated successfully with direct percutaneous interventions for acute ST-segment elevation myocardial infarction* , 2002, Critical care medicine.

[278]  R. Giugliano,et al.  Impact of Time of Presentation on Process Performance and Outcomes in ST-Segment–Elevation Myocardial Infarction: A Report From the American Heart Association: Mission Lifeline Program , 2014, Circulation. Cardiovascular quality and outcomes.

[279]  J. Struck,et al.  Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. , 2008, Journal of the American College of Cardiology.

[280]  Tom Adriaenssens,et al.  Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial , 2013, The Lancet.

[281]  M. Meuwissen,et al.  Early Detection and Treatment of the Vulnerable Coronary Plaque: Can We Prevent Acute Coronary Syndromes? , 2017, Circulation. Cardiovascular imaging.

[282]  M. Sutton,et al.  Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: results of a meta-analysis of 845 patients. FAMIS, CAPTIN and CATS Investigators. , 2000, Journal of the American College of Cardiology.

[283]  J. Ambrose,et al.  Mechanisms of Coronary Thrombosis in Cigarette Smoke Exposure , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[284]  R. Arena,et al.  Management of cardiovascular diseases in patients with obesity , 2018, Nature Reviews Cardiology.

[285]  Alan S. Go,et al.  Population trends in the incidence and outcomes of acute myocardial infarction. , 2010, The New England journal of medicine.

[286]  H. Boeing,et al.  Food groups and risk of coronary heart disease, stroke and heart failure: A systematic review and dose-response meta-analysis of prospective studies , 2019, Critical reviews in food science and nutrition.

[287]  A. Kléber,et al.  Resting Membrane Potential, Extracellular Potassium Activity, and Intracellular Sodium Activity during Acute Global Ischemia in Isolated Perfused Guinea Pig Hearts , 1983, Circulation research.

[288]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[289]  P. Shalit.  Prevention and treatment of no-reflow phenomenon by targeting the coronary microcirculation. , 2014 .

[290]  R. Jennings,et al.  Development of cell injury in sustained acute ischemia. , 1990, Circulation.

[291]  H. Thiele,et al.  One‐Year Outcomes after PCI Strategies in Cardiogenic Shock , 2018, The New England journal of medicine.

[292]  K. Nakao,et al.  Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. , 2011, Journal of cardiology.

[293]  G. Vilahur,et al.  Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease , 2012, European heart journal. Acute cardiovascular care.

[294]  S. Goto,et al.  New Antithrombotics for Secondary Prevention of Acute Coronary Syndrome , 2014, Clinical cardiology.

[295]  T. Iwasaka,et al.  Effect of angiotensin-converting enzyme inhibitor on cardiopulmonary baroreflex sensitivity in patients with acute myocardial infarction. , 2000, The American journal of cardiology.

[296]  S. Pedersen,et al.  High-degree atrioventricular block complicating ST-segment elevation myocardial infarction in the era of primary percutaneous coronary intervention. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[297]  A. Bayés‐Genís,et al.  Early ST elevation myocardial infarction in non-capable percutaneous coronary intervention centres: in situ fibrinolysis vs. percutaneous coronary intervention transfer. , 2016, European heart journal.

[298]  A. Hoes,et al.  [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.

[299]  T. Jernberg,et al.  Incidence, temporal trends, and prognostic impact of heart failure complicating acute myocardial infarction. The SWEDEHEART Registry (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies): a study of 199,851 patients , 2015, JACC. Heart failure.

[300]  Diane Lacaille,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk , 2014 .

[301]  Munir A. Winkel,et al.  Cardiovascular Mortality Associated With 5 Leading Risk Factors: National and State Preventable Fractions Estimated From Survey Data , 2015, Annals of Internal Medicine.

[302]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[303]  Richard T. Lee,et al.  Complementary Roles for Biomarkers of Biomechanical Strain ST2 and N-Terminal Prohormone B-Type Natriuretic Peptide in Patients With ST-Elevation Myocardial Infarction , 2008, Circulation.

[304]  J. Holmes,et al.  Physiological Implications of Myocardial Scar Structure. , 2015, Comprehensive Physiology.

[305]  J. Smith,et al.  Prognostic impact of early ventricular fibrillation in patients with ST-elevation myocardial infarction treated with primary PCI , 2012, European heart journal. Acute cardiovascular care.

[306]  C. Cannon,et al.  Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis , 2010, Circulation.

[307]  E. Camenzind,et al.  Coronary Embolism Among ST-Segment–Elevation Myocardial Infarction Patients: Mechanisms and Management , 2018, Circulation. Cardiovascular interventions.

[308]  R. Virmani,et al.  Pathology of the Vulnerable Plaque , 2006 .

[309]  K. Eagle,et al.  Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). , 2002 .

[310]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[311]  J. Spertus,et al.  Impact of multivessel revascularization on health status outcomes in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease. , 2015, Journal of the American College of Cardiology.

[312]  P. Armstrong,et al.  Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. , 2013, The New England journal of medicine.

[313]  Harlan M Krumholz,et al.  Time course of depression and outcome of myocardial infarction. , 2006, Archives of internal medicine.

[314]  I. Kohane,et al.  Big Data and Machine Learning in Health Care. , 2018, JAMA.

[315]  S. Yusuf,et al.  Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. , 2007, JAMA.

[316]  Deepak L. Bhatt,et al.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018, The New England journal of medicine.

[317]  G. Niccoli,et al.  Acute myocardial infarction with no obstructive coronary atherosclerosis: mechanisms and management. , 2015, European heart journal.

[318]  P. Armstrong,et al.  Transatlantic Comparison of ST-Segment Elevation Myocardial Infarction Guidelines: Insights From the United States and Europe. , 2016, Journal of the American College of Cardiology.

[319]  Brett E. Bouma,et al.  In Vivo Characterization of Coronary Atherosclerotic Plaque by Use of Optical Coherence Tomography , 2005, Circulation.

[320]  M. Pittet,et al.  Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. , 2010, Circulation.

[321]  B. Waller.  Atherosclerotic and nonatherosclerotic coronary artery factors in acute myocardial infarction. , 1989, Cardiovascular clinics.

[322]  S. Blair,et al.  Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. , 2014, Journal of the American College of Cardiology.

[323]  J. Molnar,et al.  Tissue ACE Inhibitors for Secondary Prevention of Cardiovascular Disease in Patients With Preserved Left Ventricular Function: A Pooled Meta-analysis of Randomized Placebo-controlled Trials , 2007, Journal of Cardiovascular Pharmacology and Therapeutics.

[324]  Zahi A Fayad,et al.  Atherothrombosis and high-risk plaque: part I: evolving concepts. , 2005, Journal of the American College of Cardiology.

[325]  G. Biondi-Zoccai,et al.  Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. , 2013, The American journal of cardiology.

[326]  J. Alpert,et al.  How to use high-sensitivity cardiac troponins in acute cardiac care , 2012 .

[327]  A. Jaffe,et al.  The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. , 1989, Journal of the American College of Cardiology.

[328]  Dwight Lemon,et al.  Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1 , 1987 .

[329]  D. Bernhard,et al.  The biology behind the atherothrombotic effects of cigarette smoke , 2013, Nature Reviews Cardiology.

[330]  Salim Yusuf,et al.  Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications. , 2010, European heart journal.

[331]  A. Ibrahim,et al.  Acute myocardial infarction. , 2014, Critical care clinics.

[332]  Deepak L. Bhatt,et al.  Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data , 2013, The Lancet.

[333]  T. Harr,et al.  Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: a meta-analysis of randomized controlled trials. , 2004, The American journal of medicine.

[334]  S. Doherty.  Evidence-based implementation of evidence-based guidelines. , 2006, International journal of health care quality assurance incorporating Leadership in health services.

[335]  M. Beijk,et al.  Long-term outcomes of a Caucasian cohort presenting with acute coronary syndrome and/or out-of-hospital cardiac arrest caused by coronary spasm , 2017, Netherlands Heart Journal.